Theriva Biologics, Inc. (TOVX) — 8-K Filings

8-K Filings (44)

• 8-K Filing — Dec 29, 2025
• Theriva Biologics Changes Principal Executive Offices — Dec 15, 2025 Risk: low
  On December 15, 2025, Theriva Biologics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 9605 Medical Ce
• 8-K Filing — Nov 12, 2025
• Theriva Biologics Files 8-K — Oct 29, 2025 Risk: low
  Theriva Biologics, Inc. filed an 8-K on October 29, 2025, reporting other events and financial statements. The company, formerly known as Synthetic Biologics, I
• Theriva Biologics Files 8-K with Financials and Exhibits — Oct 24, 2025 Risk: low
  On October 24, 2025, Theriva Biologics, Inc. filed an 8-K report. The filing indicates a change in the company's reporting status and includes financial stateme
• Theriva Biologics Files 8-K Report — Oct 20, 2025 Risk: low
  On October 20, 2025, Theriva Biologics, Inc. filed an 8-K report. The filing indicates that the company, formerly known as Synthetic Biologics, Inc., ADEONA PHA
• Theriva Biologics Files 8-K: Material Agreement & Equity Sales — Oct 17, 2025 Risk: medium
  On October 16, 2025, Theriva Biologics, Inc. (formerly Synthetic Biologics, Inc.) entered into a material definitive agreement. The company also reported on unr
• Theriva Biologics Files 8-K with Financials — Oct 14, 2025 Risk: low
  On October 13, 2025, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a
• Theriva Biologics Files 8-K — Oct 8, 2025 Risk: low
  On October 8, 2025, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
• Theriva Biologics Files 8-K — Oct 6, 2025 Risk: low
  Theriva Biologics, Inc. filed an 8-K on October 6, 2025, reporting on events that occurred on the same date. The filing includes information related to Regulati
• Theriva Biologics Reports Exit/Disposal Costs — Oct 2, 2025 Risk: medium
  Theriva Biologics, Inc. filed an 8-K on October 2, 2025, reporting costs associated with exit or disposal activities as of September 28, 2025. The filing detail
• Theriva Biologics Files 8-K: Officer Changes & Shareholder Votes — Sep 4, 2025 Risk: medium
  Theriva Biologics, Inc. filed an 8-K on September 4, 2025, reporting events as of August 29, 2025. The filing indicates a departure of directors or certain offi
• Theriva Biologics Files 8-K on Financials — Aug 11, 2025 Risk: low
  On August 11, 2025, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• Theriva Biologics Files 8-K — Jun 25, 2025 Risk: low
  On June 25, 2025, Theriva Biologics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 9605 Medical Center
• Theriva Biologics Files 8-K, Updates Address — Jun 20, 2025 Risk: low
  On June 20, 2025, Theriva Biologics, Inc. filed an 8-K report. The filing indicates a change in the company's business address to 9605 Medical Center Drive, Sui
• Theriva Biologics Files 8-K with Financials — Jun 2, 2025 Risk: low
  On May 27, 2025, Theriva Biologics, Inc. (formerly Synthetic Biologics, Inc.) filed an 8-K report. The filing primarily concerns financial statements and exhibi
• Theriva Biologics Files 8-K on Financials — May 14, 2025 Risk: low
  On May 14, 2025, Theriva Biologics, Inc. (formerly Synthetic Biologics, Inc.) filed an 8-K report. The filing indicates a change in the company's financial cond
• Theriva Biologics Files 8-K for Material Agreement — May 8, 2025 Risk: medium
  On May 7, 2025, Theriva Biologics, Inc. entered into a material definitive agreement. The company, formerly known as Synthetic Biologics, Inc., filed an 8-K rep
• Theriva Biologics Files 8-K with Regulatory Updates — May 7, 2025 Risk: low
  Theriva Biologics, Inc. filed an 8-K on May 7, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other ev
• Theriva Biologics Files 8-K Report — Mar 31, 2025 Risk: low
  On March 31, 2025, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial statements
• Theriva Biologics Files 8-K on Financials — Mar 6, 2025 Risk: low
  Theriva Biologics, Inc. filed an 8-K on March 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
• Theriva Biologics Files 8-K: Name Changes & Financials — Dec 5, 2024 Risk: low
  On December 5, 2024, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Financial
• Theriva Biologics Files 8-K on Financials — Nov 12, 2024 Risk: low
  On November 12, 2024, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as
• Theriva Biologics Files 8-K on Officer/Director Changes & More — Nov 1, 2024 Risk: medium
  Theriva Biologics, Inc. filed an 8-K on October 31, 2024, reporting on several key events. These include the departure of directors or certain officers, the ele
• Theriva Biologics Files 8-K: Name Changes & Financials — Oct 16, 2024 Risk: low
  On October 16, 2024, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Financial
• Theriva Biologics Files 8-K: Regulation FD, Other Events — Oct 3, 2024 Risk: low
  On October 3, 2024, Theriva Biologics, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial statem
• Theriva Biologics Enters Material Definitive Agreement — Sep 30, 2024 Risk: medium
  On September 26, 2024, Theriva Biologics, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The co
• Theriva Biologics (TOVX) Files 8-K: Office Location Update — Sep 23, 2024 Risk: low
  On September 23, 2024, Theriva Biologics, Inc. (TOVX) filed an 8-K report. The filing indicates the company's principal executive offices are located at 9605 Me
• Theriva Biologics Files 8-K on Financial Obligation — Sep 16, 2024 Risk: medium
  On September 16, 2024, Theriva Biologics, Inc. filed an 8-K report detailing a direct financial obligation. The company, formerly known as Synthetic Biologics,
• Theriva Biologics Sells Subsidiary — Sep 9, 2024 Risk: medium
  Theriva Biologics, Inc. announced on September 6, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Theriva Biologics L
• Theriva Biologics Files 8-K on Security Holder Rights — Aug 26, 2024 Risk: medium
  Theriva Biologics, Inc. filed an 8-K on August 26, 2024, reporting material modifications to security holder rights and amendments to its articles of incorporat
• Theriva Biologics Files 8-K on Security Holder Rights — Aug 16, 2024 Risk: medium
  On August 15, 2024, Theriva Biologics, Inc. filed an 8-K report detailing material modifications to the rights of its security holders. The filing also addresse
• Theriva Biologics Files 8-K on Financials — Aug 13, 2024 Risk: medium
  On August 13, 2024, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• Theriva Biologics Files 8-K: Regulation FD, Other Events — Jul 31, 2024 Risk: low
  On July 30, 2024, Theriva Biologics, Inc. (formerly Synthetic Biologics, Inc.) filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The fi
• Theriva Biologics Files 8-K — May 23, 2024 Risk: low
  Theriva Biologics, Inc. filed an 8-K on May 23, 2024, reporting on other events and financial statements. The company, formerly known as Synthetic Biologics, In
• Theriva Biologics Files 8-K Report — May 16, 2024 Risk: low
  On May 13, 2024, Theriva Biologics, Inc. filed an 8-K report detailing other events. The company, formerly known as Synthetic Biologics, Inc., is incorporated i
• Theriva Biologics Files 8-K on Financials — May 7, 2024 Risk: low
  On May 7, 2024, Theriva Biologics, Inc. (formerly Synthetic Biologics, Inc.) filed an 8-K report. The filing primarily concerns the company's results of operati
• Theriva Biologics Files 8-K: Material Agreement & Financials — May 2, 2024 Risk: medium
  On May 2, 2024, Theriva Biologics, Inc. (formerly Synthetic Biologics, Inc.) filed an 8-K report. The filing indicates an entry into a material definitive agree
• Theriva Biologics Files 8-K: Regulation FD, Other Events — Apr 23, 2024 Risk: low
  On April 23, 2024, Theriva Biologics, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial stateme
• Theriva Biologics Files 8-K with Financials — Apr 22, 2024 Risk: low
  On April 22, 2024, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and also includes a Regulation
• Theriva Biologics Files 8-K: Name Changes & Financials — Apr 16, 2024 Risk: low
  On April 16, 2024, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. Th
• Theriva Biologics Files 8-K on Financials — Mar 25, 2024 Risk: medium
  On March 25, 2024, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as we
• Theriva Biologics Files Routine 8-K for SEC Compliance — Feb 7, 2024
  Theriva Biologics, Inc. filed an 8-K on February 7, 2024, indicating a routine update to their public disclosures. This filing primarily serves to satisfy vario
• Theriva Biologics Files Routine 8-K, No New Material Events — Jan 8, 2024
  Theriva Biologics, Inc. filed an 8-K on January 8, 2024, primarily to disclose general information and confirm its current registration details with the SEC. Th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX